Sanjay Ram, MD
Infectious Disease · Worcester, MANPI 1699753194
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (38.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Sanofi-aventis U.S. LLC accounts for 70.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $23,862 and has fallen 90.3% since, to $2,310 in 2025. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $2095.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$24K
- Sanofi Pasteur Inc.$6K
- Roche Products Limited$4K
- GSK$138
- Merck$26
Across 2 payments — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$10K
What the payments were for
- Consulting fees$9,64729%
- Speaking & faculty fees$10,93433%
- Travel & lodging$12,83438%
- Food & beverage$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 7 | $23,712 |
| Sanofi Pasteur Inc. | 1 | $5,751 |
| Roche Products Limited | 4 | $3,896 |
| GSK | 2 | $138 |
| Merck | 2 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$23,631
How this compares
$33,523 in reported general payments places this provider in the 90th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Worcester
- Thomas GreenoughWorcester$83K
- Joyce FingerothWorcester$59K
- Laura GibsonWorcester$14K
- Mireya WessolosskyWorcester$8K
- Richard EllisonWorcester$4K
- Yoav GolanBoston$1.1M
- Claudia MartorellSpringfield$990K
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Peter SebenyNewburyport$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.